-
公开(公告)号:WO2014017936A2
公开(公告)日:2014-01-30
申请号:PCT/PT2013000048
申请日:2013-07-24
申请人: BIAL PORTELA & CA SA
发明人: ROSA CARLA PATRICIA DA COSTA PEREIRA , GUSMAO DE NORONHA RITA , KISS LASZLO ERNO , SOARES DA SILVA PATRICIO MANUEL VIEIRA ARAUJO , RUSSO DOMENICO , WAHNON JORGE BRUNO REIS , MATON WILLIAM
IPC分类号: C07D233/61 , A61K31/4178 , A61P31/00 , C07C209/48 , C07D233/88
CPC分类号: C07D233/64 , A61K31/4164 , A61K45/06 , C07C209/00 , C07C209/26 , C07D207/335 , C07D233/61 , C07D233/88 , C07C211/35
摘要: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.
摘要翻译: 具有以下结构的化合物:或其药学上可接受的盐或衍生物。 该化合物可用于治疗或预防选自食欲调节,肥胖症,代谢病症,恶病质,厌食症,疼痛,炎症,神经毒性,神经创伤,中风,多发性硬化症,脊髓损伤,帕金森病,左旋多巴诱导的病症 运动障碍,亨廷顿舞蹈病,吉莱斯德拉图雷特综合征,迟发性运动障碍,肌张力障碍,肌萎缩侧索硬化,阿尔茨海默病,癫痫,精神分裂症,焦虑症,抑郁症,失眠,恶心,呕吐,酒精紊乱,药物成瘾如阿片制剂,尼古丁, 酒精和精神兴奋剂,高血压,循环休克,心肌再灌注损伤,动脉粥样硬化,哮喘,青光眼,视网膜病,癌症,炎性肠病,急性和慢性肝病如肝炎和肝硬化,关节炎和骨质疏松症。
-
公开(公告)号:WO2014017938A2
公开(公告)日:2014-01-30
申请号:PCT/PT2013000050
申请日:2013-07-26
申请人: BIAL PORTELA & CA SA
IPC分类号: C07D213/00
CPC分类号: C07D401/04 , C07D213/00 , C07D213/50 , C07D213/53
摘要: A process for preparing a substituted urea compound of Formula II or Formula I, or a pharmaceutically acceptable salt or ester thereof, Formula II, Formula I the process comprising the reaction of an intermediate of Formula II' or Formula 1', Formula II', Formula I' with a carbamoyl halide of the formula: RlR2NC(=0)Hal, in a solvent consisting essentially of pyridine, wherein Hal represents Cl, F, I or Br, and wherein ring A, and Rl, R2, R5, V, W, X, Y and Z are as defined herein.
摘要翻译: 制备式II或式I的取代的脲化合物或其药学上可接受的盐或其酯,式II,式I的方法包括式II'或式1',式II'的中间体与式II' 式I'与基本上由吡啶组成的溶剂中的式R 1 R 2 NC(= O)Hal的氨基甲酰卤,其中Hal表示Cl,F,I或Br,并且其中环A和R 1,R 2,R 5,V ,W,X,Y和Z如本文所定义。
-